Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic leukemia. The CAR T cell therapy is nevertheless associated with toxicities, especially if the CARs are not entirely tumor-specific. Therefore...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Esther Drent, Renée Poels, Manon J Mulders, Niels W C J van de Donk, Maria Themeli, Henk M Lokhorst, Tuna Mutis
Format: Artigo
Sprog:Inglês
Udgivet: Public Library of Science (PLoS) 2018-01-01
Serier:PLoS ONE
Online adgang:http://europepmc.org/articles/PMC5976165?pdf=render
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker